Dual Subsartorial Versus Adductor Canal Block Versus Femoral Nerve Block for Postoperative Analgesia in Patients Undergoing Total Knee Arthroplasty

NCT ID: NCT07082374

Last Updated: 2025-07-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-24

Study Completion Date

2026-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to compare the effect of dual subsartorial block (DSB), adductor canal block (ACB), and femoral nerve block (FNB) for postoperative analgesia in patients undergoing total knee arthroplasty (TKA).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Total knee arthroplasty (TKA) offers increased joint mobility and painless ambulation to patients. Femoral nerve block (FNB) is commonly used to relieve postoperative pain and opioid consumption.

Adductor canal block (ACB) is a common analgesic intervention for postoperative pain control following TKA. The dual subsartorial block (DSB) is a novel procedure-specific and motor-sparing regional analgesia (RA) technique that may reduce overall postoperative opioid consumption when used in conjunction with multimodal analgesia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dual Subsartorial Block Adductor Canal Block Femoral Nerve Block Postoperative Analgesia Total Knee Arthroplasty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DSB group

Patients will receive dual subsartorial block (DSB).

Group Type EXPERIMENTAL

Dual subsartorial block

Intervention Type OTHER

Patients will receive dual subsartorial block (DSB).

ACB group

Patients will receive an adductor canal block (ACB).

Group Type EXPERIMENTAL

Adductor canal block

Intervention Type OTHER

Patients will receive an adductor canal block (ACB).

FNB group

Patients will receive a femoral nerve block (FNB).

Group Type EXPERIMENTAL

Femoral nerve block

Intervention Type OTHER

Patients will receive a femoral nerve block (FNB).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dual subsartorial block

Patients will receive dual subsartorial block (DSB).

Intervention Type OTHER

Adductor canal block

Patients will receive an adductor canal block (ACB).

Intervention Type OTHER

Femoral nerve block

Patients will receive a femoral nerve block (FNB).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 18 to 75 years.
* Both sexes.
* American Society of Anesthesiology (ASA) physical status I-II.
* Undergoing total knee arthroplasty (TKA) under general anesthesia.

Exclusion Criteria

* Severe valgus deformity.
* Acute/chronic kidney disease.
* Neurological deficit.
* Cognitive dysfunction.
* Local infection at the site of injection.
* Coagulopathy.
* Hypersensitivity and/or allergies to local anesthetic (LA) or any of the study medications.
* Chronic opioid consumption (daily or almost daily use of opioids for \> three months).
* Operative limb neuropathy.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tanta University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohammed Said ElSharkawy

Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tanta University

Tanta, El-Gharbia, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mohammed S ElSharkawy, MD

Role: CONTACT

00201148207870

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mohammed S Elsharkawy, MD

Role: primary

00201148207870

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

36264PR1260/6/25

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.